PA
TLX

Parallel Advisors’s Telix Pharmaceuticals TLX Stock Holding History

Parallel Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16K Buy
100
+99
+9,900% +$1.01K ﹤0.01% 3657
2026
Q1 		$13 Sell
1
-11
-92% -$84 ﹤0.01% 3822
2025
Q4 		$93 Buy
+12
New +$115 ﹤0.01% 3552

Other funds holding TLX

PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return

Parallel Advisors's TLX Position: Q2 2026 in Review

Parallel Advisors increased its Telix Pharmaceuticals (TLX) stake by 9,900% in Q2 2026, buying an estimated $1.01K and bringing the position to 100 shares worth $1.16K. The position accounts for ﹤0.01% of the portfolio, ranked #3657.

Parallel Advisors first reported a position in TLX in Q4 2025 and has held it in 3 quarters since. 20 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Parallel Advisors held 100 shares of Telix Pharmaceuticals worth $1.16K as of Q2 2026.
  • Parallel Advisors bought 99 Telix Pharmaceuticals shares in Q2 2026, an estimated $1.01K.
  • Telix Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3657 holding.
  • Parallel Advisors first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 20 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.